文章预览
SCI 23 September 2024 Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (Journal of Clinical Oncology, IF: 42.1) James Chih-Hsin Yang; Dae Ho Lee,; Jong-Seok Lee; Yun Fan; Filippo de Marinis; Eiji Iwama; Takako Inoue; Jer ́onimo Rodr ́ıguez-Cid,; Li Zhang; Cheng-Ta Yang; Emmanuel de la Mora Jimenez; Jianying Zhou; Maurice P ́erol; Ki Hyeong Lee; David Vicente; Eiki Ichihara; Gregory J. Riely; Yiwen Luo; Diana Chirovsky; M. Catherine Pietanza; Niyati Bhagwati; and Shun Lu, MD CORRESPONDENCE TO: chihyang@ntu.edu.tw PURPOSE 目的 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemet
………………………………
